t(8;16)(p11;p13) in treatment related leukemia

Jean-Loup Huret

Genetics, Dept Medical Information, UMR 8125 CNRS, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: October 2003

Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0816p11p13TreatRelID1302.html

DOI: 10.4267/2042/38048

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

Identity

Note: This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q) and -7/del(7q) not taken into account per see), published in Genes, Chromosomes and Cancer in 2002.

Epidemiology

t(8;16)(p11;p13) was found in 2% of t-MDS/t-ANLL; sex ratio: 5M/4F.

Clinics

Age at diagnosis of the primary disease 33 yrs (range 6-70); age at diagnosis of the t-MDS/t-ANLL: 41 yrs (range 7-71). Median interval was 17 mths (range: 13-202). Primary disease was a solid tumor in 9 of 9 cases; treatment was radiotherapy in 1 case, chemotherapy in 2 of 9 cases, or both (6/9). Treatment included topoisomerase II inhibitors in 6 of 8 cases and alkylating agents in 7/8.

Prognosis

Median survival was very poor: 5 mths, with 39% of patients surviving at 1 yr, and none at 2 yrs.

Cytogenetics

Additional anomalies

Complex karyotypes were found in 4 of 9 cases.

Result of the chromosomal anomaly

Hybrid gene

Description

5′ MOZ -3′ CBP
References